نتایج جستجو برای: biologic drugs

تعداد نتایج: 280824  

2013
Barbara A. Goff

The standard treatment of advanced ovarian cancer is rapidly changing. As we begin to understand that epithelial ovarian cancer is a heterogeneous disease, our treatment strategies are evolving to include novel biologic drugs that specifically exploit altered pathways. Surgery remains an essential component in the treatment of ovarian cancer; however, the importance of surgical specialization a...

2014
Glenn Haugeberg Knut Bjørn Helgetveit Øystein Førre Torhild Garen Hege Sommerseth Anne Prøven

BACKGROUND Osteoporosis is a well-known extra articular manifestation in rheumatoid arthritis (RA). Biologic disease modifying anti rheumatic drugs (DMARDs) has been shown to be superior to synthetic DMARDs to reduce bone destruction including generalized bone loss in RA. Our aim was to study short- and long term changes in hip and spine bone mineral density (BMD) in early RA patients treated d...

2015
Mahipal Reddy

The present study was based on the FDA suggested system for humans, according to the Center for Drug Evaluation and Research (CDER) regulates the combination of products has been divided based on the dosage form preparation, that include a product contained two or more drugs that is known as fixed combination according to the section 21 CFR 300.50 [1]. The final product contains two more regula...

Journal: :International journal of STD & AIDS 2017
D L Fink L Hedley R F Miller

Biologic therapies are injectable immunomodulatory agents directed against specific immune cell or chemical targets. They have transformed the lives of HIV-uninfected individuals with severe inflammatory conditions including psoriasis, rheumatoid arthritis, and ulcerative colitis. The perceived increased infection risk associated with these agents means that HIV-infected individuals have not be...

Journal: :Arthritis care & research 2012
Liana Fraenkel Ellen Peters Peter Charpentier Blair Olsen Lanette Errante Robert T Schoen Valerie Reyna

OBJECTIVE Despite the importance of achieving tight control, many patients with rheumatoid arthritis (RA) are not effectively treated with disease-modifying antirheumatic drugs. The objective of this study was to develop a decision support tool to inform RA patients with ongoing active disease about the risks and benefits related to biologic therapy. METHODS We developed a balanced, web-based...

2012
Dongxing Zha

Biologic pharmaceuticals are gaining in both market share and clinical utility compared with small molecule therapeutics (Projan et al., 2004). Global biologic drug sales reached $93 billion in 2009 and the sales are expected to grow at least twice as fast as those of small molecules (McCamish and Woollett, 2011). The rapid market growth and the promise of successful rate of developing biologic...

2011
Andrew Taylor Hanish Bagga

Objectives. To investigate which rheumatoid arthritis (RA) disease activity measures are being collected in patients receiving glucocorticoids, non-biologic or biologic disease-modifying antirheumatic drugs (DMARDs) in Australian rheumatology practice. Methods. A retrospective audit of medical records was conducted from eight rheumatology practices around Australia. Each rheumatologist recruite...

Journal: :iranian endodontic journal 0
akbar khayat department of endodontics, school of dentistry, shiraz university of medical sciences, shiraz, iran. [email protected] shayan fatehi endodontist, shiraz, iran

introduction: complicated crown- root fractures, extended caries and iatrogenic destruction often result in insufficient sound tooth structures and compromise the biologic width. two common options for re-establishing flap with osseous surgery. although some advantages are related to these two options, but coronal movement of gingival and alveolar bone in orthodontic extrusion, esthetic problem...

2012
Pamela F Weiss

Juvenile idiopathic arthritis (JIA) is a chronic, inflammatory disease of unknown etiology. The enthesitis-related arthritis (ERA) JIA category describes a clinically heterogeneous group of children including some who have predominately enthesitis, enthesitis and arthritis, juvenile ankylosing spondylitis, or inflammatory bowel disease-associated arthropathy. ERA accounts for 10%-20% of JIA. Co...

Journal: :Clinical and experimental rheumatology 2002
C Antoni J Braun

The development of the anti-TNF therapies is a milestone in the therapy of rheumatic diseases. As in all new treatment opportunities it is of concern whether all potential undesired side effects have been evaluated within the clinical trials which have lead to approval of the drugs. Postmarketing experience and pharmacovigilance programs are necessary to determine the overall safety profile of ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید